ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+0.00%Jun 10, 2026, 00:00 UTC
Aldeyra Therapeutics, Inc. elected Todd C. Brady, M.D., Ph.D. as a Class III director and appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, effective June 9, 2026.
Jun 5, 2026, 01:02 UTC
Aldeyra Therapeutics expects near-term FDA feedback on its dry eye disease candidate reproxalap after receiving a third complete response letter.
Source: